Aurobindo Pharma, one of the major pharmaceuticals companies of India, has announced that the US Food and Drug Administration (FDA) has given the company a permission to market its 300 mg Cefdinir Capsules. The company has made the announcement on Monday through a filing to the Bombay Stock Exchange (BSE) and said that it has also received the US FDA approval to market its Abbreviated New Drug Application (ANDA) Cefdinir Capsules in the US market.
A top official of the company informed that the Cefdinir is actually used in order to treat or prevent the infections that are proven or strongly suspected to be caused by bacteria. The official added that this drug is a generic equivalent of the Abbott Laboratories Omnicef capsules that are used to treat patients, who have mild to moderate infections caused by susceptible strains of micro-organisms. According to a source from the Aurobindo Pharma, the company had already received the US FDA approval to market 125 mg and 250 mg strengths of Cefdinir Capsules. The company is based in Hyderabad and the source further said that this is the 62nd ANDA approval that the company has received so far.
|
|
|
|
|
| Posted : 1/22/2008 |
|
|
|
|
